Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells

Fig. 2

Knockdown of Annexin A2 increased cisplatin sensitivity in vivo. a A549/DDP cells were transfected with Control shRNA or Annexin A2 shRNA, Annexin A2 expression was analyzed by Western blot. b-d A549/DDP cells transfected with Control shRNA or Annexin A2 shRNA were injected to the right shoulder of nude mice. Tumor-bearing mice were treated with either PBS or Cisplatin (3 mg/kg body weight per day) for 4 weeks, tumor sizes were measured at every 3 days (b). At the end of treatment, tumor were excised (c) and tumor weight were measured (d). e-f Tumor tissues were resected, fixed, sectioned, and placed on slides. Tumor specimens were subjected to immunohistochemical staining with antibodies specific to Annexin A2 (e) and Ki67 (f). *p < 0.05

Back to article page